Acne Vulgaris Market Size is expected to grow by 2034, estimates DelveInsight

Posted on
by

Acne Vulgaris Market Size is expected to grow by 2034, estimates DelveInsight

DelveInsight’s comprehensive report titled “Acne Vulgaris Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of acne vulgaris. The report presents historical and projected epidemiological data covering Total Prevalent Cases of Acne Vulgaris, Total Diagnosed Prevalent Cases of Acne vulgaris, Gender specific Diagnosed Prevalent Cases of Acne Vulgaris and Severity-Specific Diagnosed prevalent Cases of Acne Vulgaris.

 

Explore the intricate details of the Acne Vulgaris Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Acne Vulgaris Market Forecast. Click here to stay ahead in healthcare innovation @ Acne Vulgaris Market Size

 

Key Takeaways from the Acne Vulgaris Market Report

  • June 2024:- Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.- A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Efficacy and Safety of Clascoterone Cream 1% in Treatment of Subjects With Facial Acne Vulgaris. The primary objective of this study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
  • June 2024:- Sanofi- A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age
  • June 2024:- AbbVie- An International, Multicenter, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars.
  • June 2024:- UCB Biopharma SRL- A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa.
  • June 2024:- Incyte Corporation- A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa. The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
  • As per the analysis, in Japan, the prevalence of acne vulgaris among the students was 58.6%, with the average onset at 13.3 years of age.
  • The evaluation of acne severity revealed that “mild acne” was the most common form across all subgroups, affecting 92% of adult females, 82% of adult males, 89% of teenage females, and 77% of teenage males, in Italy.
  • In a survey of employees in Germany, the overall prevalence of acne was found to be 4.2%. Other studies indicate that the prevalence of acne in adolescents aged 9 to 20 can reach up to 95%, without distinguishing between clinical and “physiologic” acne.
  • The leading Acne Vulgaris Companies such as Timber Pharmaceuticals, BioPharmX, Kintor Pharma, Botanix Pharmaceuticals, and others
  • Promising Acne Vulgaris Therapies such as Clascoterone, DMT310, Winlevi (clascoterone) 1% & Duac gel, Erythromycin 4% topical gel formulation, ASC40, and others.

 

Delve deep into the Acne Vulgaris Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Acne Vulgaris Market Forecast. Click here to shape the future @ Acne Vulgaris Epidemiology Insights

 

Acne Vulgaris Overview

Acne vulgaris is an inflammatory disorder of the pilosebaceous unit, which runs a chronic course and it is elf-limiting. Acne vulgaris is triggered by propionibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone.

 

Acne Vulgaris Epidemiology Insights

  • Total Prevalent Cases
  • Total Diagnosed Prevalent Cases
  • Gender-specific Diagnosed Prevalent Cases
  • Severity-specific Diagnosed Prevalent Cases
  • Treated Cases

 

Navigate the complexities of the Acne Vulgaris Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Acne Vulgaris Market Forecast. Click here to get more insights @ Acne Vulgaris Treatment Market

 

Acne Vulgaris Drug Market

According to DelveInsight’s estimates, the Acne Vulgaris market size in the 7MM is expected to show positive growth, during the forecast period (2024–2034), mainly attributed to the increasing prevalence of acne vulgaris, growing awareness and diagnoses, and the new product launches. The expected increase in treated cases of acne vulgaris in the US is driven by factors such as improved awareness, advancements in treatment options, changing lifestyles, and evolving societal attitudes towards skincare and self-care. These factors collectively contribute to a greater demand for acne treatment and management services. Furthermore these cases are subjected to change during the forecast period (2024-2034).

 

Acne Vulgaris Treatment Landscape

Acne treatment depends on the individual’s age and sex, the extent and severity of the acne, the period since it has been present, and response to previous treatments. Treatment for mild acne includes topical anti-acne preparations, lasers and lights. Treatment for moderate acne includes antibiotics such as tetracyclines and/or antiandrogens such as birth controlpills. Treatment for severe acne may require a course of oral isotretinoin. Azelaic acid is a naturally occurring acid produced by yeast. It has antibacterial properties. A 20% azelaic acid cream or gel seems to be as effective as many conventional acne treatments when used twice a day.

 

Acne Vulgaris Market Insights

Several treatments are available for acne vulgaris, there is a need for more effective long-term maintenance therapies to prevent acne recurrence and minimize the risk of scarring. Some individuals with acne vulgaris may not respond adequately to existing treatments, including antibiotics, topical retinoids, and hormonal therapies. There is a need for alternative treatment options for these resistant cases. Many acne treatments, particularly oral medications like isotretinoin, can have significant side effects. There is a need for therapies that effectively treat acne while minimizing adverse effects, especially in adolescents and young adults. Acne vulgaris is a heterogeneous condition, and treatment efficacy can vary greatly among individuals. There is a need for personalized treatment approaches that take into account factors such as acne severity, skin type, hormonal status, and potential comorbidities.

 

Unlock insights into the Acne Vulgaris Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Acne Vulgaris Market Forecast. Click here @ Acne Vulgaris Market Drivers and Barriers

 

Acne Vulgaris Marketed Drugs

  • AKLIEF: Galderma Labs

AKLIEF (trifarotene) Cream, 0.005%, is indicated for the topical treatment of acne. It selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin, making it the first topical retinoid to do so. Trifarotene is the first new retinoid molecule to receive US FDA approval for acne treatment in over 20 years. AKLIEF Cream is specifically studied and proven to treat both facial (forehead, cheeks, nose, and chin) and truncal (chest, shoulders, and back) acne, providing healthcare professionals and acne patients with an additional treatment option.

  • ARAZLO: Ortho Dermatologics/Bausch Health

ARAZLO (tazarotene) Lotion, 0.045%, is a prescription medication used topically to treat acne in individuals aged 9 years and older. It effectively addresses various acne symptoms, including blackheads, whiteheads, and other types of pimples. Notably, ARAZLO is the first tazarotene acne treatment available in lotion form, offering strong efficacy coupled with favorable tolerability.

  • CABTREO: Ortho Dermatologics/Bausch Health

CABTREO (clindamycin phosphate, adapalene, and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1% is a prescription medication specifically designed for topical use on the skin to treat acne vulgaris in adults and children aged 12 years and older. It is the first and only FDA-approved fixed-dose, triple-combination topical treatment for acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide to effectively address acne symptoms.

 

Acne Vulgaris Emerging Drugs

The acne vulgaris Drug Market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, including BioPharmX, Kintor Pharma, Botanix Pharmaceuticals, and others, have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.

  • BPX-01: Timber Pharmaceuticals/BioPharmX

BPX-01 (topical minocycline, 2%) is being developed for the treatment of moderate-to-severe acne. In a Phase 2b study, treatment with BPX-01 showed a statistically significant reduction in the number of acne lesions, with no serious adverse events related to study treatment. BPX-01 is a hydrophilic topical gel with fully solubilized minocycline capable of penetrating the skin to deliver the antibiotic to where acne develops in the pilosebaceous unit. Currently, the drug is in Phase II of clinical development for the treatment of acne.

  • KX-826: Kintor Pharma

KX-826 is being developed by Kintor Pharmaceuticals, for Acne vulgaris. This agent targets mild to moderate patients and is being developed in topical formulation. The company is looking forward to the next step of filing IND to initiate the clinical development of the drug.

  • BTX 1503: Botanix Pharmaceuticals

Botanix Pharmaceuticals is advancing BTX 1503, a novel topical treatment designed for moderate to severe acne. This formulation harnesses synthetic cannabidiol as the active drug component, in conjunction with Botanix’s proprietary Permetrex drug delivery technology. Notably, the company has released Phase II results and is now preparing for Phase III clinical trials for the treatment of acne.

 

Scope of the Acne Vulgaris Market Report

  • Coverage- 7MM
  • Acne Vulgaris Companies- Timber Pharmaceuticals, BioPharmX, Kintor Pharma, Botanix Pharmaceuticals, and others
  • Acne Vulgaris Therapies- Clascoterone, DMT310, Winlevi (clascoterone) 1% & Duac gel, Erythromycin 4% topical gel formulation, ASC40, and others.
  • Acne Vulgaris Market Dynamics: Acne Vulgaris Market drivers and Exocrine Pancreatic Insufficiency Market Barriers
  • Acne Vulgaris Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Acne Vulgaris Unmet Needs, KOL’s views, Analyst’s views, Acne Vulgaris Market Access and Reimbursement

 

Gain a strategic edge in the Acne Vulgaris Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Acne Vulgaris Market Forecast. Click here to lead in advancements @ Acne Vulgaris Clinical Trials Assessment

 

Table of Content

1 Key Insights

2 Report Introduction

3 Acne Vulgaris Market Overview at a Glance

4 Epidemiology and Market Methodology

5 Executive Summary

6 Acne Vulgaris Key Events

7 Disease Background and Overview: Acne Vulgaris

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Therapies

11 Emerging Therapies

12 Acne Vulgaris: Seven Major Market Analysis

13 Key Opinion Leaders’ Views

14 Unmet Needs

15 SWOT Analysis

16 Acne Vulgaris Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/